|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0014 USD | -97.32% |
|
0.00% | +16.67% |
RegeneRx Biopharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.076761 million compared to USD 0.076761 million a year ago. Net loss was USD 1.73 million compared to USD 1.6 million a year ago.
Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 2.11K | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +56.46% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +2.70% | 8.71B |
REGENERX BIOPHARMACEUTICALS, INC. 
